Drug Profile
Beremagene geperpavec - Krystal Biotech
Alternative Names: B-VEC; Bercolagene telserpavec; Beremagene geperpavec-svdt; HSV1-COL7; KB-103; VYJUVEKLatest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action COL7A1 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Epidermolysis bullosa dystrophica
Most Recent Events
- 01 Mar 2024 Krystal Biotec plans a clinical trial in Epidermolysis bullosa dystrophica in USA (Ophthalmic) in 2H of 2024
- 29 Feb 2024 Krystal Biotech has patent protection which cover methods of delivering targeted therapeutics for skin delivery in Australia before February 2024
- 29 Feb 2024 Krystal Biotech has patent protection which cover pharmaceutical composition of B-VEC including prophylactic, palliative or therapeutic relief of wound in Japan and Mexico before February 2024